ALK and non-small cell lung carcinoma: For patients presenting with epidermal growth factor receptor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-rearranged NSCLC, targeted therapies have shown efficacy and antitumor activity in the central nervous system (CNS) [10,11].